



Abbott India Limited  
Godrej BKC, Plot C-68, "G"Block,  
15-16th Floor, Bandra-Kurla Complex,  
Near MCA Club, Bandra (E),  
Mumbai - 400 051. India

Registered Office:  
3, Corporate Park,  
Sion Trombay Road,  
Mumbai - 400 071.India

Tel: (91-22) 5046 1000/2000  
Fax : (91-22) 5016 9400  
E-mail : webmasterindia@abbott.com  
Website : www.abbott.co.in  
CIN: L24239MH1944PLC007330

September 19, 2024

Corporate Relations Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400 001

**Scrip Code: 500488**

Dear Sirs,

**Subject: Abbott India Limited signs a non-exclusive patent license agreement with Takeda Pharmaceuticals Company Limited to commercialize Vonoprazan, a novel molecule in the gastrointestinal therapy area.**

This is to inform you that Abbott India Limited (hereafter referred to as "Abbott") has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company Limited (hereafter referred to as "Takeda") to market and distribute "Vonoprazan" in India under the brand name "Vonefi".

Vonoprazan (PCAB or Potassium Competitive Acid Blocker) addresses severe acid related disorders like reflux esophagitis through a once daily dose. Current treatments for reflux esophagitis, a condition under the Gastroesophageal Reflux Disease (GERD) umbrella, have several limitations including the need for multiple dosing for effectiveness, especially when the condition is severe. Vonoprazan, a first-of-its kind therapy, will help make it easier for patients to comply with their treatment and manage their condition better.

This license will enable Abbott, a leader in the gut health space, to enhance access to this novel therapy to more patients across India.

This is for your records and information.

For **Abbott India Limited**

**Sangeeta Shetty**  
**Company Secretary**  
**Membership No.: ACS 18865**